5 articles
Ocular graft-versus-host disease (oGvHD) manifests in 60-80% of patients undergoing allogeneic haematopoietic stem cell transplantation, due to donor T cells incorrectly identifying recipient tissue as foreign, leading to an immunological attack by the donor cells1.
It is well recognised that tear film lipid layer instability is one of the hallmarks of evaporative dry eye disease (DED), yet most artificial tears are water-based and thus do little to replenish the disrupted lipid layer.
It is well recognised that tear film lipid layer instability is one of the hallmarks of evaporative dry eye disease (DED), yet most artificial tears are water-based and thus do little
Developing new drugs for the treatment of ocular diseases can be a time-consuming and costly undertaking. The trip from laboratory to market can take anywhere between 10 to 20 years and will cost
Developing new drugs for the treatment of ocular diseases can be a time-consuming and costly undertaking. The trip from laboratory to market can take anywhere between 10 to 20 years and will cost around US$1 billion. Fig 1 outlines a breakdown of the 2013 United States Food and Drug Administration